$228.84
+0.60(0.26%)
Mkt Cap $14.0B
$137.41
$242.09
52-Week Range
At a Glance
AI-generated6-K
Ascendis Pharma A/S filed updated Articles of Association effective 30 March 2026, disclosing current share capital of DKK 62,376,846 and ongoing Board authorizations for warrants, capital increases, and convertible bonds.$14.0B
Market Cap
$619M
Revenue
-$196M
Net Income
Employees1,017
Fundamentals
How The Business Makes Money
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001612042
ISINUS04351P1012
CUSIP04351P101
Phone45 70 22 22 44
AddressTuborg Boulevard 12, Hellerup, 2900, DK
SEC EDGAR